Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors

Cancer Recurrence, Clinical Trials, Metastatic Castration Resistant Prostate Cancer (MCRPC), Non-Metastatic Castration Resistant Prostate Cancer (nMCRPC)

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT05488548
Phase: Phase 1
Trial Summary: A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Epigenetix, Inc.
Acronym:

Pin It on Pinterest